Growth Metrics

Adma Biologics (ADMA) Long-Term Investments (2020 - 2025)

Adma Biologics' Long-Term Investments history spans 6 years, with the latest figure at $8.6 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 52.02% year-over-year to $8.6 million; the TTM value through Dec 2025 reached $8.6 million, up 52.02%, while the annual FY2025 figure was $8.6 million, 52.02% up from the prior year.
  • Long-Term Investments reached $8.6 million in Q4 2025 per ADMA's latest filing, down from $8.8 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $9.1 million in Q2 2025 to a low of $2.5 million in Q2 2021.
  • Average Long-Term Investments over 5 years is $5.5 million, with a median of $5.2 million recorded in 2024.
  • Peak YoY movement for Long-Term Investments: soared 93.04% in 2021, then dropped 16.98% in 2024.
  • A 5-year view of Long-Term Investments shows it stood at $4.1 million in 2021, then rose by 17.27% to $4.8 million in 2022, then dropped by 2.1% to $4.7 million in 2023, then increased by 21.13% to $5.7 million in 2024, then skyrocketed by 52.02% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Long-Term Investments are $8.6 million (Q4 2025), $8.8 million (Q3 2025), and $9.1 million (Q2 2025).